The biotech company highlighted in today’s article, specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer, is one that the author has on his list of high-return-potential candidates. Before taking a position in the stock, however, he cautions that investors need to be aware of one issue of concern that could have important consequences for the stock in the short and medium term. For more, CLICK HERE.